INTERNATIONAL CONGRESS OF
CancerGenetics
Investigating the effect of Sinopharm and AstraZeneca vaccine injection on intra-tumoral microbiome of TNBC mice model
-
Mobina Mirkarimi,1 Flora Forouzesh,2 Mohammad Amin Javidi,3,*
1. Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. 2- Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
2. Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
3. Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
- Introduction: SARS-CoV-2 virus has a single-stranded, globular RNA. Infection with SARS-CoV-2 virus is mainly associated with fever, dry cough, fatigue, lethargy and loss of appetite[1]. People with cancer were 75% more susceptible to the most severe form of this virus than other people[2,3] (figure1). The most common type of cancer in women is breast cancer, the most metastatic molecular subtype of that is triple negative breast cancer [4]. Recent studies since 2019 have shown that the microbiota can influence the progression of cancer suppression[5].Microbiota refers to a collection of microbes living in the body and microbiome is defined as all the genomes of this microbiota[6]. Our main goal in this study was to investigate the effect of injecting Sinopharm and AstraZeneca vaccines on the amount of intra-tumoral bacteria in a triple-negative breast cancer mouse model. The effect of Sinopharm and AstraZeneca vaccine in increasing anti-tumor properties, i.e. reducing metastasis and tumor size, has been proven [7] (figure 2), and the mechanism of effect of Sinopharm and AstraZeneca vaccines on increasing anti-tumor properties has been investigated in this article
- Methods: 4T1 mouse cells (TNBC) was cultured in vitro, and these cells was subsequently used to produce TNBC mice models. The mouse model was injected with Sinopharm vaccines in one dose (S1) and two dose (S2) and AstraZeneca vaccine in one dose (A1) and two dose (A2). After 30 days, tumor samples from all mice were dissected. Total RNA extracted from these tumors, and real-time PCR test was performed to measure the expression of 16s rRNA gene based on realQ Plus 2x Master Mix SYBR Green protocol (figure 3). Data analysis performed according to the obtained Cts and using the formula 2^-dct. Statistical analysis: Data analysis and graphs were done with the help of Graph pad prism statistical software. The t-test was used to check the difference between the means between the two groups, and p-value less than 0.05 was considered significant.
- Results: Real-time PCR results showed that the average relative expression of the 16S rRNA gene of the mouse tumor sample that received the first dose of Sinopharm vaccine (S1 = 0.092), the second dose of Sinopharm vaccine (S2 = 0.0087) and after the injection of the first dose of AstraZeneca vaccine (A1 equal to 0.3) compared to the control sample in which no vaccine was injected, had a decrease in expression, but in the sample that was injected with the second dose of AstraZeneca vaccine (A2 equal to 0.78), no significant difference was observed compared to the control sample (figures 4-6).
- Conclusion: Real-time PCR results showed that the injection of Sinopharm and AstraZeneca vaccines led to a decrease in the relative expression of the 16S rRNA gene compared to the control sample, which proves the decrease in the population of bacteria inside the tumor after the injection of the mentioned vaccines. On the other hand, AstraZeneca and Sinopharm vaccines lead to an increase in anti-tumor properties; hence, one of the mechanisms of which can be proposed for the seen anti-cancer effect of the vaccination might be through affecting the intra-tumoral microbiota
- Keywords: Triple-negative breast cancer, covid-19 vaccines, Sinopharm vaccine, AstraZeneca vaccine
